Giant Prolactinoma and Primary Amenorrhea with an Infantile Uterus: A Case Report

Munazzah Rafique1*, Solaiman Alobaid2 and Dania Aljaroudi2

1Department of Obstetrics and Gynecology, Women’s Specialized Hospital, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia; 2Reproductive Endocrinology and Infertility Medicine Department, Women’s Specialized Hospital, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia

ABSTRACT

Giant prolactinomas are rare pituitary gland tumours found in paediatric and adolescent patients. The pituitary gland controls metabolism, growth, sexual maturation, reproduction, blood pressure, and other vital physical functions. A 15-year-old girl presented with headache, blurred vision, primary amenorrhea and significantly high prolactin (PRL) levels with baseline level of 344,727 µg/L. Turner syndrome, Müllerian agenesis, hypothalamic amenorrhea, and primary ovarian insufficiency were excluded by laboratory and radiologic tests. Initial brain computed tomography revealed a giant pituitary adenoma and ultrasonography revealed an infantile uterus. Pituitary gland resection confirmed prolactinoma. With medical treatment, menstruation was restored uterine and ovarian parameters were improved with increased endometrial thickness and ovaries showing follicles. However, symptom recurrence and resistance to treatment warranted surgical and radiological interventions. This case report calls attention to the role of prolactin in uterine development and the need to include prolactin level in key investigations in patients with primary amenorrhea.

Keywords: Giant prolactinoma; Adenoma; Amenorrhea; Pituitary gland

INTRODUCTION

The pituitary gland is a crucial structure in the hypothalamic-pituitary-gonadal axis and plays an integral role in sexual maturation during puberty [1]. Prolactin levels can increase because of medications, pituitary adenoma, hypothyroidism, or mass effects, which can compromise normal hypothalamic inhibition [2]. Prolactin tumours are the most common secreting pituitary adenoma and are frequently microadenomas (<10 mm diameter) or, less commonly, giant prolactinomas (>4 cm diameter) [3]. The pituitary gland grows during adolescence and its volume correlates to circulating plasma total testosterone and oestradiol levels [1]. Prolactinoma frequently occur in females with female-to-male ratio is approximately 10:1. Prolactinomas have a prevalence of 100/million population in the paediatric and adolescent age group and constitute less than 2% of all intracranial tumors [4]. Mostly patients present with infertility and menstruation dysfunction. However, if remain unrecognized and untreated they can result in significant morbidity [5]. Sex differences at presentation and tumour behaviour have been recognized, with >70% occurring in females, while males often present with larger, more aggressive tumours [6]. Paediatric (age, <16 years) and adolescent (age, ≤ 20 years) prolactinomas are very rare and typically diagnosed in the late stage [7].

The functional diversity of prolactin is responsible for differences in the initial clinical presentation of hyperprolactinaemia [8]. Prolactinomas are functioning adenomas and can induce visual disturbances and body morphological changes [9]. Hyperprolactinaemic children present with various initial clinical presentations including growth and puberty disorders, obesity, galactorrhea, and oligomenorrhea or amenorrhea [8-10]. These symptoms are consequence of prolactin-induced suppression of gonadotrophin-releasing hormone and its negative feedback at the pituitary and gonadal levels [11]. Primary amenorrhea is defined as no menarche by age 13 when there is no pubertal development, no menarche 5 years after initial breast development, or no menses in patients aged ≥ 15 years [12]. It can be caused by chromosomal abnormalities (e.g., Turner syndrome), anatomic anomalies (e.g., Müllerian agenesis), hypothalamic amenorrhea,
hyperprolactinaemia, hypopituitarism (due to craniopharyngioma, other sellar tumors, pituitary stalk damage) or primary ovarian insufficiency [12].

Elevated prolactin levels inhibit the secretion and effect of gonadotrophins and necessitate the need for magnetic resonance imaging (MRI) of the pituitary [1]. Treatment of prolactinomas may involve dopamine agonist administration or surgical resection [2]. Our objective in this paper is to report a rare case of prolactinoma.

**CASE REPORT**

A 15-year-old girl with no relevant medical, family, or psychosocial history was admitted to the Neurology Department of King Fahad Medical City (Riyadh, Saudi Arabia) for headache. Twelve months before presentation, the patient developed frontal and temporal headache with blurred vision that was unresponsive to paracetamol. Some months later, she developed loss of concentration accompanied by fatigue. She was referred to the Reproductive Endocrinology and Infertility Medicine Department for primary amenorrhea. She had no symptoms of hypothyroidism, adrenal insufficiency, galactorrhea, or polycystic ovary syndrome.

Upon admission, the patient underwent a clinical evaluation and medical tests. On physical examination, she was alert and hemodynamically stable with no postural drop in blood pressure or features of cortisol or growth hormone excess. She was 151 cm tall, weigh 67 kg, with a body mass index (BMI) of 29.5, normal pubertal development, and no galactorrhea. Her secondary sexual characteristics and breast development were normal. However, optic discs were pale, with bilateral hemianopia. She also had mild left upper limb weakness. Laboratory test findings were as follows: elevated prolactin level, 344,727 µg/L; serum cortisol level, 186 nmol/L; serum adrenocorticotropic hormone level, 3.0 pg/mL; thyroid-stimulating hormone level, 1.3 mIU/L; free thyroxine level, 14.1 pmol/L; luteinizing hormone level, 5.5 IU/L, follicle-stimulating hormone level, 5.6 IU/L; testosterone level, 4.9 nmol/L; and growth hormone level, 1.7 µg/L (indicating partial anterior hypopituitarism). Abdominal ultrasonography revealed an infantile uterus (2.31 cm³), endometrial thickness of 0.2 mm, and ovaries without follicles (Figure 1).

MRI revealed a giant invasive prolactinoma (7.2 × 6.1 × 7.9 cm³) that had extended to an extra-axial tumour at the anterior skull base and the middle cranial fossa and was invading the sella turcica and right cavernous sinus. Destruction of the related base bony structures was observed with the tumour drawn-out laterally through the right foramen ovale. Brain computed tomography showed a large extra-axial tumour with a sellar component associated with a midline shift and mild brain swelling (Figure 2).

On admission in 2014, she was treated with oral cabergoline (0.5 mg four times per week), hydrocortisone, and thyroxine in standarded doses. She started irregular and scanty menstruation with medical treatment. However, her headache and vision problem persisted even after 6 months of treatment; she therefore underwent surgical resection for the pituitary macroadenoma via a suboccipital approach. The histopathology was consistent with that of a pituitary adenoma. Subsequently, her prolactin level decreased from 344,727 to 14,114 µg/L within 6 days, and she was discharged and advised to take cabergoline 0.25 µg twice weekly. Post-treatment MRI showed improvement (Figure 3).

Moreover, post-treatment ultrasonography revealed that her uterus measured 4.55 × 1.33 cm³ with an endometrial thickness of 2 mm and both ovaries contained small follicles. These findings showed improved uterine and ovarian dimensions (Figure 4).

However, within 2 years of surgery despite of being on maximum dose of cabergoline (2 mg/week), she experienced bilateral hemianopia, headache, secondary amenorrhea, and increased prolactin level of 38,531 µg/L. MRI showed an interval increase in lesion size, particularly in that of the sellar components, with the most significant increase seen in the craniocaudal dimension. The lesion invaded the bilateral cavernous sinuses and sphenoidal sinus with suprasellar extension and encasement of the cavernous segment of both the internal and anterior cerebral arteries, which maintained patent flow. A multidisciplinary team diagnosed an atypical giant pituitary macroadenoma with a post-resection residual tumour that showed significant progression in size since the previous MRI. Therefore, external beam radiation therapy was

---

**Figure 1:** Abdominal ultrasonography before treatment showing an infantile uterus and ovaries.

**Figure 2:** Pre-treatment view: An axial T2-weighted image with gadolinium revealed a large diffusely enhanced lesion invading the middle cranial fossa and cavernous sinus. Middle: sagittal T2-weighted MRI with gadolinium.

**Figure 3:** Postsurgical T1-weighted gadolinium images before and early post-treatment.

**Figure 4:** Post-surgical gadolinium images (T1-weighted) showing the residual tumour and the presence of the right cavernous sinus and sella turcica.
Figure 4: Uterus and ovaries after treatment. Ultrasonography revealed that her uterus measured 4.55 × 1.33 cm² with an endometrial thickness of 2 mm and both ovaries contained small follicles. She started, and her visual symptoms improved; a follow-up brain MRI showed a minimal decrease in lesion size (Figure 5).

DISCUSSION

Giant prolactinomas are rare and usually present in men, while microprolactinomas predominate in women. Contrarily, our patient was an adolescent female. Some studies have suggested that pituitary tumours are more aggressive and invasive in paediatric patients than in adults [13], comparable to our patient.

An assessment of secondary sexual characteristics by Tanner stages, are widely used to evaluate growth and developmental age during adolescence that helps in evaluating physical growth and detecting certain diseases and disorders associated with adolescence. These stages of growth correlate highly with other pubertal events [14]. Paediatric prolactinomas are frequently associated with delayed puberty as high prolactin levels affect hypothalamic–gonadotrophic activity [13,14]. The most common symptoms of prolactinoma are gynaecomastia and hypogonadism in males and primary amenorrhoea and galactorrhoea in females [13,15]. In women after puberty, symptom duration mainly reflects disease duration. However, the influence of sex on tumour behaviour and response to treatment remains unclear [16]. The main complaint of our patient was impaired vision and headache, and she was later referred for primary amenorrhoea.

Kanter et al. reported increased invasiveness of adenomas when symptom onset was during pubertal years compared with cases wherein symptoms first appeared after puberty [17]. This was consistent with our case wherein symptoms appeared in the prepubertal stage and were reported almost 1 year after onset. Invasive macro adenomas generally invade adjacent structures, but do not metastasise [3]. Although the cystic components of prolactinomas are well defined, an invasive giant prolactinoma is extremely rare. Patients with prolactinoma and higher prolactin values (>4,000 mU/L) have a reduction in serum levels of both FSH and LH, consistent with direct pituitary gonadotrope dysfunction [18].

Dopamine agonist administration is the first-choice treatment for paediatric and adult prolactinomas. Resistance to medication, intolerable side effects, and non-adherence to medication are major problems in medical treatment [16]. Although the response of giant macroprolactinomas to medical therapy is unpredictable [7], our patient showed a moderately reduced prolactin level within 6 weeks of treatment with a high-dose dopamine agonist [19]. Hyperprolactinemia is more common in females, and cabergoline is highly effective and practical to use in adolescents due to its biweekly dosing. Surgery should be considered in childhood [20]. However, symptom persistence warranted surgical resection. The role of surgery in the treatment of these lesions is limited. Complete surgical resection is difficult and biochemical cure is rare [18]. The degree of cavernous sinus invasion is often significant, precluding complete resection. However, we chose surgical treatment for the giant tumour with a large suprasellar extension and mass effect in our patient. The observed clinical improvement later on decreased due to the increased residual size of the treatment-resistant adenoma. Prolactin level is a good indicator of tumour recurrence in the follow-up period [21].

Subsequently, serum prolactin levels in our patient increased. Radiotherapy was started due to symptom recurrence and cavernous sinus invasion by the tumour after multidisciplinary team discussion. However, the follow-up MRI showed no change in the adenoma size. Generally, giant macroprolactinomas are sensitive to dopamine agonist therapy; as in our patient who showed improved visual symptoms, menstruation, uterine parameters, and prolactin levels. Nonetheless, surgery may often be necessary for giant prolactinomas, which are usually refractory to treatment.

CONCLUSION

In our patient, menstruation was restored and uterine parameters improved with high-dose cabergoline treatment. However, her other symptoms persisted. Secondary amenorrhea can occur in the setting of a giant invasive macroprolactinoma; therefore, prolactin levels should be a routine part of the hormonal evaluation of primary amenorrhea.

AUTHOR CONTRIBUTIONS

RM compiled endocrine data and authored the manuscript. JD and AS co-authored the manuscript and performed the literature search. All authors were directly or indirectly involved in the care of the patient. JD is the physician principally responsible for the care of the patient and co-authored the manuscript.

ACKNOWLEDGEMENTS

Reproductive Endocrine and Infertility and Medicine Department.

CONFLICTS OF INTEREST

No conflicts of interest.
FUNDING
This study received no funding.

ETHICAL APPROVAL
The IRB approved the study protocol.

CONSENT
Informed consent was obtained from the patient for publication of this case report and any accompanying images.

GUARANTOR
Dr. Dania Al-Jaroudi.

REFERENCES